Kanał XCUR
XC

Exicure, Inc.

XCUR · NASDAQ

$1.25 +0.56% (+$0.01)
1M +6.96%
Market Cap $8.60M
P/E Ratio -
Div. Yield -
ROE 237.91%
Piotroski F-Score Weak
1/9
Valuation
0 /100
Expensive
P/B 8.81x
P/E N/A
EV/FFO N/A
Growth
0 /100
Declining
Book val. growth 35.92%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor
ROIC 93.88%
Asset turnover 0.00x
ROE 237.91%
Debt
48 /100
Moderate
Debt/Equity 0.00x
Int. coverage -8,917.00x
Current ratio 0.56x
Stability
1 /100
Unstable
Beta 3.62x
Profitable years 0
EPS volatility 181.89%

Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej

Zapytaj StockBota o XCUR
Online

O spółce

Exicure, Inc. is a biopharmaceutical company focused on developing novel therapeutics based on the technology of therapeutic coding. Its main product platform is based on a technology called Spherical Nucleic Acid (SNA™), which enables the creation of three-dimensional structures of nucleic acids that have the potential to modulate gene expression. Exicure aims to utilize this technology to develop therapeutics for various indications, including oncological diseases, dermatological conditions, and neurological disorders. The company also engages in research and development of therapeutic vaccines based on SNA™ technology. Exicure collaborates with pharmaceutical companies and academic institutions on the development and commercialization of its products. Shares of Exicure, Inc. may be an interesting investment opportunity for investors following the pharmaceutical industry and biopharmaceutical research.

Opis nie jest jeszcze dostępny w Twoim języku, więc tekst jest po angielsku.

Sector

Healthcare

Industry

Biotechnology

CEO

Jungsoo Kim

Employees

1

Headquarters

Redwood City

Nadchodzące wydarzenia

12 LIS

Earnings

Upcoming earnings report

53d

Używamy niezbędnych plików cookie do działania strony oraz opcjonalnych analitycznych plików cookie do pomiaru ruchu. Zobacz naszą Politykę prywatności.